Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting this debilitating disease.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease.
We are revolutionizing the treatment of heart disease through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy
- TN-201 is a potentially curative gene therapy intended to address genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the Myosin Binding Protein C3 (MYBPC3) gene,
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
- Series C round led by RTW Investments, LP; RA Capital Management; Fidelity Management & Research Company; and funds and accounts advised by T. Rowe Price Associates, Inc.; and joined by existing investors including The Column Group,
Navigating the Complexities of AAV Scale-Up and Manufacturing
Tenaya’s senior vice president of manufacturing, Kee-Hong Kim, Ph.D., spoke with John Sterling, editor of Genetic Engineering & Biotechnology News in an executive roundtable interview to discuss the challenges and complexities involved with AAV manufacturing for gene therapy. Kee shared his perspective on the resources, tools and expertise needed to scale up production, as well as how Tenaya is innovating and strategizing to overcome these challenges.Read More
Join Our Team
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and collaboration? Our team combines deep biological insights, sophisticated drug development technologies and a boundless determination to change the future for the millions of people affected by heart disease.